Nano-Drug Carriers Based on Membrane Fluidity

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1107

Special Issue Editor

Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, ICBMS, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR 5246, GEMBAS Team, 69622 Villeurbanne, France
Interests: membranes; lipid nano-particles; carrier-membrane interactions

Special Issue Information

Dear Colleagues,

Cell membranes undergo profound transformations during the evolution of various pathologies. These transformations may provide new biomarkers or new therapeutic targets. Modifications in the type or in the density of various receptors or sugars at the cell surface have already been used for targeting purposes, but modifications in the biophysical properties of the membranes, due to intimate changes in lipid composition, such as membrane fluidity, are still underexplored.

This special issue proposes to focus on advances and novelties in the conception and use of nano-drug carriers based on membrane fluidity or more generally membrane physical properties. Nanomedicines with controlled membrane composition, and thus controlled fluidity, are currently developed to maximize their biophysical interactions with membrane lipids of various pathologic targets. In the meanwhile, membrane fluidity seems to be a key factor in the conception of novel nanomedicines with increased stability in body fluids and reduced interaction with circulatory components.

Developing novel nanomedicines to deliver molecules with therapeutic potential, designed to enhance drug delivery and carrier stability in blood, based on membrane fluidity is a key issue and a promising strategy in therapeutics and research applications.

Dr. Ofélia Maniti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nano-drug carriers
  • membrane fluidity
  • lipid nano-particles
  • carrier stability in body fluids
  • carrier-membrane interactions
  • particle penetration in tissue
  • particle biodistribution

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2701 KiB  
Article
Carrier–Tumor Cell Membrane Interactions for Optimized Delivery of a Promising Drug, 4(RS)-4-F4t-Neuroprostane
by Ariana Abawi, Céline Thomann, Giovanna Lollo, Thierry Granjon, Emma Petiot, Anna Bérot, Camille Oger, Valérie Bultel-Poncé, Alexandre Guy, Jean-Marie Galano, Thierry Durand, Agnès Girard-Egrot and Ofelia Maniti
Pharmaceutics 2023, 15(12), 2739; https://doi.org/10.3390/pharmaceutics15122739 - 07 Dec 2023
Viewed by 796
Abstract
Nanomedicines engineered to deliver molecules with therapeutic potentials, overcoming drawbacks such as poor solubility, toxicity or a short half-life, are targeted towards their cellular destination either passively or through various elements of cell membranes. The differences in the physicochemical properties of the cell [...] Read more.
Nanomedicines engineered to deliver molecules with therapeutic potentials, overcoming drawbacks such as poor solubility, toxicity or a short half-life, are targeted towards their cellular destination either passively or through various elements of cell membranes. The differences in the physicochemical properties of the cell membrane between tumor and nontumor cells have been reported, but they are not systematically used for drug delivery purposes. Thus, in this study, a new approach based on a match between the liposome compositions, i.e., membrane fluidity, to selectively interact with the targeted cell membrane was used. Lipid-based carriers of two different fluidities were designed and used to deliver 4(RS)-4-F4t-Neuroprostane (F4t-NeuroP), a potential antitumor molecule derived from docosahexaenoic acid (DHA). Based on its hydrophobic character, F4t-NeuroP was added to the lipid mixture prior to liposome formation, a protocol that yielded over 80% encapsulation efficiency in both rigid and fluid liposomes. The presence of the active molecule did not modify the liposome size but increased the liposome negative charge and the liposome membrane fluidity, which suggested that the active molecule was accommodated in the lipid membrane. F4t-NeuroP integration in liposomes with a fluid character allowed for the selective targeting of the metastatic prostate cell line PC-3 vs. fibroblast controls. A significant decrease in viability (40%) was observed for the PC-3 cancer line in the presence of F4t-NeuroP fluid liposomes, whereas rigid F4t-NeuroP liposomes did not alter the PC-3 cell viability. These findings demonstrate that liposomes encapsulating F4t-NeuroP or other related molecules may be an interesting model of drug carriers based on membrane fluidity. Full article
(This article belongs to the Special Issue Nano-Drug Carriers Based on Membrane Fluidity)
Show Figures

Figure 1

Back to TopTop